GKB Ophthalmics peers

·Pharma & HealthChart ›

Companies like GKB Ophthalmicslatest year

GKB OphthalmicsGKB · FY23 · this company
Market cap₹30.2
P/E—
Sales growth—
ROE−10.5%
Fabtech TechnologiesFABTECH · FY26
Open ›
Market cap₹543
P/E12.22×
Sales growth−24.2%
ROE9.1%
Laxmi DentalLAXMIDENTL · FY26
Open ›
Market cap₹975
P/E32.07×
Sales growth+13.9%
ROE12.8%
Tarsons ProductsTARSONS · FY26
Open ›
Market cap₹1,617
P/E112.99×
Sales growth+20.7%
ROE2.3%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GKB₹60.01

GKB Ophthalmics Limited

· Pharma & Health
₹ CrorePeersFABTECHLAXMIDENTLTARSONSFISCHERMcap ₹30.2 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
GKB
FY23
FABTECH
FY26
LAXMIDENTL
FY26
TARSONS
FY26
Peer
Average
Valuation — at last close
P/E—◆ 12.22×32.07×112.99×52.43×
P/B◆ 1.10×1.29×4.01×2.55×2.62× -58%
EV/EBITDA◆ -37.45×10.50×21.97×16.74×16.41× -328%
Market Cap₹30.2 Cr₹543 Cr₹975 Cr₹1,617 Cr₹1,045 Cr -97%
Growth
Revenue YoY (latest Q)—-24.20%13.87%◆ 20.66%3.44%
Net Income YoY (latest Q)—-46.54%◆ 23.83%-180.99%-67.90%
Profitability
EBITDA Margin-3.95%8.52%15.62%◆ 27.91%17.35% -123%
Net Income Margin-10.39%9.34%◆ 10.41%3.39%7.71% -235%
Return on Common Equity-10.47%9.14%◆ 12.83%2.26%8.08% -230%
Return on Capital Employed-11.50%6.65%◆ 11.21%2.34%6.73% -271%
Return on Assets-5.86%5.87%◆ 9.99%1.26%5.71% -203%
Credit & Quality
Total Debt/Equity0.41×0.10×◆ 0.00×0.60×0.23× +76%
Interest Coverage-2.43×7.14×◆ 20.15×0.95×9.41× -126%
Scale — latest FY
Revenue / Total Income₹27.7 Cr₹411 Cr₹278 Cr₹423 Cr₹370 Cr -93%
Net Income−₹2.9 Cr₹38.4 Cr₹28.9 Cr₹14.3 Cr₹27.2 Cr -111%
Total Assets₹49.1 Cr₹654 Cr₹294 Cr₹1,186 Cr₹711 Cr -93%
EPS₹-5.72₹10₹5.53₹2.69₹6.07 -194%
Book Value per Share₹54.63₹94.43₹44.27₹119.29₹86 -36%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.